HC Wainwright Reduces Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Investment analysts at HC Wainwright cut their Q3 2026 earnings per share estimates for Gossamer Bio in a research note issued on Wednesday, August 26th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.05) per share for the quarter, down from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2026 earnings at ($0.26) EPS, Q1 2027 earnings at ($0.02) EPS, Q2 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.09) EPS and FY2029 earnings at ($0.03) EPS.

Several other research firms have also recently issued reports on GOSS. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 target price on the stock in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gossamer Bio in a research note on Friday, August 14th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $3.20.

Gossamer Bio Price Performance

NASDAQ GOSS opened at $0.17 on Friday. The company has a market cap of $39.92 million, a P/E ratio of -0.24 and a beta of 2.04. Gossamer Bio has a 12 month low of $0.11 and a 12 month high of $3.87. The company has a 50-day moving average of $0.17 and a 200-day moving average of $0.41.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.04. The business had revenue of $9.24 million during the quarter, compared to analyst estimates of $3.63 million.

Hedge Funds Weigh In On Gossamer Bio

A number of large investors have recently modified their holdings of the company. MMA Asset Management LLC purchased a new stake in shares of Gossamer Bio during the 4th quarter worth about $31,000. Soltis Investment Advisors LLC purchased a new position in Gossamer Bio in the fourth quarter valued at approximately $31,000. Beacon Pointe Advisors LLC acquired a new position in Gossamer Bio during the fourth quarter valued at approximately $34,000. Ieq Capital LLC acquired a new position in Gossamer Bio during the fourth quarter valued at approximately $35,000. Finally, Janney Montgomery Scott LLC purchased a new stake in Gossamer Bio during the fourth quarter worth approximately $39,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.